Recombinant PhpA Protein, a Unique Histidine Motif-Containing Protein from Streptococcus pneumoniae, Protects Mice against Intranasal Pneumococcal Challenge
Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue IAI About IAI Subscribers Authors Reviewers Advertisers Inquiries from the...
Saved in:
| Published in | Infection and Immunity Vol. 69; no. 6; pp. 3827 - 3836 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.06.2001
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Classifications
Services
IAI
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
Spotlights in the Current Issue
IAI
About
IAI
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
Connect to IAI
IAI
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0019-9567
Online ISSN:
1098-5522
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
IAI
.asm.org, visit:
IAI
|
|---|---|
| AbstractList | The multivalent pneumococcal conjugate vaccine is effective against both systemic disease and otitis media caused by serotypes contained in the vaccine. However, serotypes not covered by the current conjugate vaccine may still cause pneumococcal disease. To address these serotypes and the remaining otitis media due to Streptococcus pneumoniae, we have been evaluating antigenically conserved proteins from S. pneumoniae as vaccine candidates. A previous report identified a 20-kDa protein with putative human complement C3-proteolytic activity. By utilizing the publicly released pneumococcal genomic sequences, we found the gene encoding the 20-kDa protein to be part of a putative open reading frame of approximately 2,400 bp. We recombinantly expressed a 79-kDa fragment (rPhpA-79) that contains a repeated HxxHxH motif and evaluated it for vaccine potential. The antibodies elicited by the purified rPhpA-79 protein were cross-reactive to proteins from multiple strains of S. pneumoniae and were against surface-exposed epitopes. Immunization with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) or a mutant cholera toxin, CT-E29H (for intranasal immunization), protected CBA/N mice against death and bacteremia, as well as reduced nasopharyngeal colonization, following intranasal challenge with a heterologous pneumococcal strain. In contrast, immunization with the 20-kDa portion of the PhpA protein did not protect mice. These results suggest that rPhpA-79 is a potential candidate for use as a vaccine against pneumococcal systemic disease and otitis media. ABSTRACT The multivalent pneumococcal conjugate vaccine is effective against both systemic disease and otitis media caused by serotypes contained in the vaccine. However, serotypes not covered by the current conjugate vaccine may still cause pneumococcal disease. To address these serotypes and the remaining otitis media due to Streptococcus pneumoniae , we have been evaluating antigenically conserved proteins from S. pneumoniae as vaccine candidates. A previous report identified a 20-kDa protein with putative human complement C3-proteolytic activity. By utilizing the publicly released pneumococcal genomic sequences, we found the gene encoding the 20-kDa protein to be part of a putative open reading frame of approximately 2,400 bp. We recombinantly expressed a 79-kDa fragment (rPhpA-79) that contains a repeated HxxHxH motif and evaluated it for vaccine potential. The antibodies elicited by the purified rPhpA-79 protein were cross-reactive to proteins from multiple strains of S. pneumoniae and were against surface-exposed epitopes. Immunization with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) or a mutant cholera toxin, CT-E29H (for intranasal immunization), protected CBA/N mice against death and bacteremia, as well as reduced nasopharyngeal colonization, following intranasal challenge with a heterologous pneumococcal strain. In contrast, immunization with the 20-kDa portion of the PhpA protein did not protect mice. These results suggest that rPhpA-79 is a potential candidate for use as a vaccine against pneumococcal systemic disease and otitis media. Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue IAI About IAI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy Connect to IAI IAI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0019-9567 Online ISSN: 1098-5522 Copyright © 2014 by the American Society for Microbiology. For an alternate route to IAI .asm.org, visit: IAI The multivalent pneumococcal conjugate vaccine is effective against both systemic disease and otitis media caused by serotypes contained in the vaccine. However, serotypes not covered by the current conjugate vaccine may still cause pneumococcal disease. To address these serotypes and the remaining otitis media due to Streptococcus pneumoniae , we have been evaluating antigenically conserved proteins from S. pneumoniae as vaccine candidates. A previous report identified a 20-kDa protein with putative human complement C3-proteolytic activity. By utilizing the publicly released pneumococcal genomic sequences, we found the gene encoding the 20-kDa protein to be part of a putative open reading frame of approximately 2,400 bp. We recombinantly expressed a 79-kDa fragment (rPhpA-79) that contains a repeated HxxHxH motif and evaluated it for vaccine potential. The antibodies elicited by the purified rPhpA-79 protein were cross-reactive to proteins from multiple strains of S. pneumoniae and were against surface-exposed epitopes. Immunization with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) or a mutant cholera toxin, CT-E29H (for intranasal immunization), protected CBA/N mice against death and bacteremia, as well as reduced nasopharyngeal colonization, following intranasal challenge with a heterologous pneumococcal strain. In contrast, immunization with the 20-kDa portion of the PhpA protein did not protect mice. These results suggest that rPhpA-79 is a potential candidate for use as a vaccine against pneumococcal systemic disease and otitis media. |
| Author | Ying Zhang Vicki Barniak Amy W. Masi Ken Mountzouros Margaret K. Hostetter Bruce A. Green |
| AuthorAffiliation | Departments of Immunology 1 and Bacteriology 2 Research, Wyeth Lederle Vaccines, West Henrietta, New York, and Department of Children's Health, Yale University School of Medicine, New Haven, Connecticut 3 |
| AuthorAffiliation_xml | – name: Departments of Immunology 1 and Bacteriology 2 Research, Wyeth Lederle Vaccines, West Henrietta, New York, and Department of Children's Health, Yale University School of Medicine, New Haven, Connecticut 3 |
| Author_xml | – sequence: 1 surname: YING ZHANG fullname: YING ZHANG organization: Department of Immunology, Wyeth Lederle Vaccines, West Henrietta, New York, United States – sequence: 2 givenname: Amy W surname: MASI fullname: MASI, Amy W organization: Department of Bacteriology Research, Wyeth Lederle Vaccines, West Henrietta, New York, United States – sequence: 3 givenname: Vicki surname: BARNIAK fullname: BARNIAK, Vicki organization: Department of Immunology, Wyeth Lederle Vaccines, West Henrietta, New York, United States – sequence: 4 givenname: Ken surname: MOUNTZOUROS fullname: MOUNTZOUROS, Ken organization: Department of Bacteriology Research, Wyeth Lederle Vaccines, West Henrietta, New York, United States – sequence: 5 givenname: Margaret K surname: HOSTETTER fullname: HOSTETTER, Margaret K organization: Department of Children's Health, Yale University School of Medicine, New Haven, Connecticut, United States – sequence: 6 givenname: Bruce A surname: GREEN fullname: GREEN, Bruce A organization: Department of Bacteriology Research, Wyeth Lederle Vaccines, West Henrietta, New York, United States |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14163395$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11349048$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks1uEzEUhS1URNPCK4BZwKoT_D-2xCaKCo3Uigjo2nIcOzGasdOxA-q78LB4SGhhxcq69nfs63PPGTiJKToAXmE0xZjId4vZYirUVEypJG1DJRVTghB-AiYYKdlwTsgJmNQd1Sgu2lNwlvO3WjLG5DNwijFlCjE5AT8_O5v6VYgmFrjc7mZwOaTiQryABt7GcLd38CrkEtYhOniTSvDNPMViQgxx8weGfkg9_FIGtyvJJmv3Ge6i2_cpBuMuDpgtGd4E66DZVHUucBHLYKLJpoPL3_CorMV8a7rOxY17Dp5602X34rieg9sPl1_nV831p4-L-ey6sRzR0lCyNh5x7qRakRUnngnO1kp6Q9eEYSydbbGXHDu_sogYxz0xmGIvFEVEenoO3h_u3e1XvVtbNzbW6d0QejPc62SC_vckhq3epO9aSYZwlb89yodU_cpF9yFb13UmurTPukWSqRah_4K4laJVoq1gewDtkHIenH_oBSM9BkDXAGihtNBjAPQYAD0GoCpf_v2VR91x4hV4cwRMrmb7OgEb8iPHsKBU8cq9PnDbsNn-CIPTJvc6VCsenqW_ALQ6ytc |
| CODEN | INFIBR |
| CitedBy_id | crossref_primary_10_3389_fcimb_2022_949469 crossref_primary_10_1128_IAI_72_5_2659_2670_2004 crossref_primary_10_1128_IAI_73_2_981_989_2005 crossref_primary_10_1371_journal_pone_0060116 crossref_primary_10_1177_00034894051140S110 crossref_primary_10_1128_IAI_01148_08 crossref_primary_10_1128_IAI_71_12_7043_7052_2003 crossref_primary_10_1128_microbiolspec_GPP3_0028_2018 crossref_primary_10_3390_vaccines9030209 crossref_primary_10_1007_s10096_023_04560_6 crossref_primary_10_1097_01_inf_0000261198_90649_04 crossref_primary_10_1586_14760584_3_5_597 crossref_primary_10_1016_j_vaccine_2013_11_096 crossref_primary_10_1007_s00018_012_1234_8 crossref_primary_10_1155_2013_490346 crossref_primary_10_1177_000348940511401S01 crossref_primary_10_1016_j_febslet_2005_08_066 crossref_primary_10_1128_IAI_00378_10 crossref_primary_10_1128_mBio_01985_19 crossref_primary_10_1016_j_vaccine_2007_01_065 crossref_primary_10_1128_IAI_00699_13 crossref_primary_10_1177_00034894051140S105 crossref_primary_10_3389_fcimb_2022_929483 crossref_primary_10_3390_vaccines7010009 crossref_primary_10_1128_spectrum_03050_23 crossref_primary_10_1186_s12865_024_00617_z crossref_primary_10_1128_IAI_00562_13 crossref_primary_10_1016_j_jprot_2015_06_011 crossref_primary_10_1186_s41479_016_0007_9 crossref_primary_10_1080_21505594_2020_1792080 crossref_primary_10_1016_j_pep_2011_02_013 crossref_primary_10_1099_jmm_0_001103 crossref_primary_10_3109_1040841X_2013_813902 crossref_primary_10_1016_j_tim_2012_06_004 crossref_primary_10_1016_j_tim_2011_06_003 crossref_primary_10_1080_21645515_2018_1430541 crossref_primary_10_1016_j_molimm_2005_06_016 crossref_primary_10_1371_journal_ppat_0030120 crossref_primary_10_1371_journal_ppat_1002622 crossref_primary_10_1016_j_xphs_2017_06_003 crossref_primary_10_1128_IAI_73_7_4245_4252_2005 crossref_primary_10_1016_j_vaccine_2021_04_068 crossref_primary_10_1007_s12010_014_0749_x crossref_primary_10_3181_0809_RM_269 crossref_primary_10_1080_21505594_2021_1889812 crossref_primary_10_1128_CVI_00050_09 crossref_primary_10_1128_JB_188_2_378_388_2006 crossref_primary_10_1016_j_vaccine_2006_04_012 crossref_primary_10_1046_j_1365_2958_2001_02610_x crossref_primary_10_3389_fimmu_2023_1278346 crossref_primary_10_3389_fcimb_2022_832254 crossref_primary_10_1016_j_vaccine_2011_05_051 crossref_primary_10_1016_j_vaccine_2016_10_061 crossref_primary_10_1371_journal_pone_0078916 crossref_primary_10_1016_j_vaccine_2008_01_029 crossref_primary_10_3389_fimmu_2019_01212 crossref_primary_10_1128_IAI_00811_09 crossref_primary_10_1371_journal_pone_0081168 crossref_primary_10_1080_10408410600822942 crossref_primary_10_1128_IAI_70_10_5604_5611_2002 crossref_primary_10_1096_fj_08_119537 crossref_primary_10_1016_j_micinf_2013_12_002 crossref_primary_10_1099_mic_0_042184_0 crossref_primary_10_1128_CVI_00293_15 crossref_primary_10_1016_j_vaccine_2009_05_071 crossref_primary_10_1099_mic_0_28551_0 crossref_primary_10_1002_prca_200780048 crossref_primary_10_1016_j_vaccine_2020_04_050 crossref_primary_10_1111_j_1574_6968_2010_02162_x crossref_primary_10_1128_CMR_00008_11 |
| Cites_doi | 10.1016/S0021-9258(19)52451-6 10.4049/jimmunol.161.8.4115 10.1097/00006454-200004000-00036 10.1016/S0898-6568(97)00175-7 10.1016/S0264-410X(99)00530-7 10.1016/S0140-6736(05)62222-2 10.1086/315388 10.1128/iai.62.1.319-324.1994 10.1093/nar/7.6.1513 10.1089/mdr.1999.5.85 10.1016/S0264-410X(00)00058-X 10.1128/IAI.68.2.796-800.2000 10.1016/S0002-9343(99)00105-9 10.1128/iai.58.10.3293-3299.1990 10.1111/j.1365-2958.1997.mmi494.x 10.1086/315722 10.1086/513980 10.1093/infdis/170.3.600 10.1006/mpat.1996.0038 10.1038/227680a0 10.1128/jb.156.1.281-290.1983 10.1093/infdis/153.4.682 10.1084/jem.160.2.386 10.1086/313608 10.1093/infdis/148.1.131 10.1046/j.1365-2958.1997.5111879.x 10.1074/jbc.273.36.22957 10.1111/j.1530-0277.1997.tb04500.x |
| ContentType | Journal Article |
| Copyright | 2002 INIST-CNRS Copyright © 2001, American Society for Microbiology 2001 |
| Copyright_xml | – notice: 2002 INIST-CNRS – notice: Copyright © 2001, American Society for Microbiology 2001 |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7QO 8FD C1K FR3 P64 7X8 5PM |
| DOI | 10.1128/IAI.69.6.3827-3836.2001 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Biotechnology Research Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Engineering Research Database CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1098-5522 |
| Editor | Moore, R. N. |
| Editor_xml | – sequence: 1 givenname: R. N. surname: Moore fullname: Moore, R. N. |
| EndPage | 3836 |
| ExternalDocumentID | 10_1128_IAI_69_6_3827_3836_2001 11349048 14163395 iai_69_6_3827 |
| Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI 24162 |
| GroupedDBID | --- -DZ -~X .55 .GJ 08R 0R~ 18M 29I 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 85S AAPBV AAUGY ABOCM ACGFO ADBBV AENEX AFMIJ AGCDD AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CS3 D0S DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HYE HZ~ H~9 IH2 IQODW J5H KQ8 L7B MVM NEJ O9- OHT OK1 P2P RHF RHI RNS RPM RSF SJN TR2 TWZ UCJ UPT VH1 VQA W2D W8F WH7 WHG WOQ X7M XFK Y6R ZA5 ZGI ZXP ~KM AGVNZ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7QO 8FD C1K FR3 P64 7X8 5PM |
| ID | FETCH-LOGICAL-c503t-32daf055e89b2b52f4654d98fa3d24118ec71f851efbc02ae5f2a131f693028f3 |
| IEDL.DBID | RPM |
| ISSN | 0019-9567 |
| IngestDate | Tue Sep 17 21:17:16 EDT 2024 Sat Aug 17 00:01:05 EDT 2024 Sun Sep 29 07:35:10 EDT 2024 Thu Sep 12 18:18:33 EDT 2024 Sat Sep 28 07:37:14 EDT 2024 Sun Oct 22 16:04:49 EDT 2023 Wed May 18 15:27:53 EDT 2016 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Still disease Middle ear disease Diseases of the osteoarticular system Systemic Histidine Antigenicity Streptococcal infection Systemic disease Bacteria Micrococcales ENT disease Recombinant protein Serotype Anthropogenic factor Human Rodentia Vaccine Protein A Streptococcus pneumoniae Infection Streptococcaceae Vertebrata Mammalia Mouse Aminoacid Bacteriosis Otitis media Conjugation |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c503t-32daf055e89b2b52f4654d98fa3d24118ec71f851efbc02ae5f2a131f693028f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Corresponding author. Mailing address: Wyeth-Lederle Vaccines, 211 Bailey Rd., West Henrietta, NY 14586-9728. Phone: (716) 273-7681. Fax: (716) 273-7515. E-mail: zhangy4@war.wyeth.com. |
| PMID | 11349048 |
| PQID | 17867967 |
| PQPubID | 23462 |
| PageCount | 10 |
| ParticipantIDs | highwire_asm_iai_69_6_3827 pubmedcentral_primary_oai_pubmedcentral_nih_gov_98401 pubmed_primary_11349048 proquest_miscellaneous_17867967 crossref_primary_10_1128_IAI_69_6_3827_3836_2001 proquest_miscellaneous_70849700 pascalfrancis_primary_14163395 |
| PublicationCentury | 2000 |
| PublicationDate | 2001-06-01 |
| PublicationDateYYYYMMDD | 2001-06-01 |
| PublicationDate_xml | – month: 06 year: 2001 text: 2001-06-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States |
| PublicationTitle | Infection and Immunity |
| PublicationTitleAlternate | Infect Immun |
| PublicationYear | 2001 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | 6886479 - J Infect Dis. 1983 Jul;148(1):131-7 8827703 - Microb Pathog. 1996 Jul;21(1):17-22 10639448 - Infect Immun. 2000 Feb;68(2):796-800 9780183 - J Immunol. 1998 Oct 15;161(8):4115-21 10762564 - J Infect Dis. 2000 Apr;181(4):1330-6 6381634 - J Exp Med. 1984 Aug 1;160(2):386-97 8077717 - J Infect Dis. 1994 Sep;170(3):600-8 14907713 - J Biol Chem. 1951 Nov;193(1):265-75 10619740 - Clin Infect Dis. 2000 Jan;30(1):100-21 9754717 - Cell Signal. 1998 Jul;10(7):491-7 3950449 - J Infect Dis. 1986 Apr;153(4):682-93 10432269 - Microb Drug Resist. 1999 Summer;5(2):85-9 9242797 - Lancet. 1997 Jul 26;350(9073):233-4 7505262 - Infect Immun. 1994 Jan;62(1):319-24 10783042 - Pediatr Infect Dis J. 2000 Apr;19(4):394-7 10781860 - Vaccine. 2000 Jun 1;18(24):2723-34 10451012 - Am J Med. 1999 Jul 26;107(1A):69S-76S 10699322 - Vaccine. 2000 Mar 6;18(17):1743-54 9364908 - Mol Microbiol. 1997 Sep;25(5):819-29 9722517 - J Biol Chem. 1998 Sep 4;273(36):22957-61 1698178 - Infect Immun. 1990 Oct;58(10):3293-9 6148377 - J Gen Microbiol. 1984 Jun;130(6):1481-7 5432063 - Nature. 1970 Aug 15;227(5259):680-5 10915081 - J Infect Dis. 2000 Aug;182(2):497-508 9438523 - Alcohol Clin Exp Res. 1997 Dec;21(9):1630-7 6619096 - J Bacteriol. 1983 Oct;156(1):281-90 9086139 - J Infect Dis. 1997 Apr;175(4):839-46 388356 - Nucleic Acids Res. 1979 Nov 24;7(6):1513-23 9379902 - Mol Microbiol. 1997 Aug;25(4):727-39 e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 Beesley J. (e_1_3_2_3_2) 1984; 130 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 Yamamoto M. (e_1_3_2_33_2) 1998; 161 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 |
| References_xml | – ident: e_1_3_2_18_2 doi: 10.1016/S0021-9258(19)52451-6 – volume: 161 start-page: 4115 year: 1998 ident: e_1_3_2_33_2 article-title: A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A publication-title: J. Immunol. doi: 10.4049/jimmunol.161.8.4115 contributor: fullname: Yamamoto M. – ident: e_1_3_2_27_2 doi: 10.1097/00006454-200004000-00036 – ident: e_1_3_2_24_2 doi: 10.1016/S0898-6568(97)00175-7 – ident: e_1_3_2_20_2 – ident: e_1_3_2_23_2 doi: 10.1016/S0264-410X(99)00530-7 – ident: e_1_3_2_11_2 doi: 10.1016/S0140-6736(05)62222-2 – ident: e_1_3_2_19_2 doi: 10.1086/315388 – ident: e_1_3_2_26_2 doi: 10.1128/iai.62.1.319-324.1994 – ident: e_1_3_2_4_2 doi: 10.1093/nar/7.6.1513 – ident: e_1_3_2_14_2 doi: 10.1089/mdr.1999.5.85 – ident: e_1_3_2_31_2 doi: 10.1016/S0264-410X(00)00058-X – ident: e_1_3_2_5_2 doi: 10.1128/IAI.68.2.796-800.2000 – ident: e_1_3_2_6_2 doi: 10.1016/S0002-9343(99)00105-9 – ident: e_1_3_2_7_2 doi: 10.1128/iai.58.10.3293-3299.1990 – volume: 130 start-page: 1481 year: 1984 ident: e_1_3_2_3_2 article-title: Immunocytochemical labelling of Bacteroides nodosus pili using an immunogold technique publication-title: J. Gen. Microbiol. contributor: fullname: Beesley J. – ident: e_1_3_2_25_2 doi: 10.1111/j.1365-2958.1997.mmi494.x – ident: e_1_3_2_29_2 doi: 10.1086/315722 – ident: e_1_3_2_32_2 doi: 10.1086/513980 – ident: e_1_3_2_28_2 – ident: e_1_3_2_2_2 doi: 10.1093/infdis/170.3.600 – ident: e_1_3_2_30_2 doi: 10.1006/mpat.1996.0038 – ident: e_1_3_2_16_2 doi: 10.1038/227680a0 – ident: e_1_3_2_22_2 doi: 10.1128/jb.156.1.281-290.1983 – ident: e_1_3_2_15_2 doi: 10.1093/infdis/153.4.682 – ident: e_1_3_2_17_2 – ident: e_1_3_2_21_2 doi: 10.1084/jem.160.2.386 – ident: e_1_3_2_12_2 doi: 10.1086/313608 – ident: e_1_3_2_10_2 doi: 10.1093/infdis/148.1.131 – ident: e_1_3_2_9_2 doi: 10.1046/j.1365-2958.1997.5111879.x – ident: e_1_3_2_8_2 doi: 10.1074/jbc.273.36.22957 – ident: e_1_3_2_13_2 doi: 10.1111/j.1530-0277.1997.tb04500.x |
| SSID | ssj0014448 |
| Score | 2.0006127 |
| Snippet | Classifications
Services
IAI
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit... The multivalent pneumococcal conjugate vaccine is effective against both systemic disease and otitis media caused by serotypes contained in the vaccine.... ABSTRACT The multivalent pneumococcal conjugate vaccine is effective against both systemic disease and otitis media caused by serotypes contained in the... |
| SourceID | pubmedcentral proquest crossref pubmed pascalfrancis highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 3827 |
| SubjectTerms | Administration, Intranasal Animals Antibodies, Bacterial - blood Bacterial diseases Bacterial Proteins - genetics Bacterial Proteins - immunology Bacteriology Biological and medical sciences Endopeptidases - chemistry Endopeptidases - genetics Endopeptidases - immunology Endopeptidases - metabolism Experimental bacterial diseases and models Fundamental and applied biological sciences. Psychology Histidine - chemistry Humans Immunization Infectious diseases Male Medical sciences Mice Mice, Inbred CBA Microbial Immunity and Vaccines Microbiology Molecular Sequence Data Nasopharynx - microbiology Otitis Media - microbiology Otitis Media - prevention & control PhpA protein Pneumococcal Infections - microbiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - immunology Recombinant Proteins - genetics Recombinant Proteins - immunology Recombinant Proteins - metabolism Sequence Analysis, DNA Streptococcal Vaccines Streptococcus pneumoniae Streptococcus pneumoniae - immunology Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies |
| Title | Recombinant PhpA Protein, a Unique Histidine Motif-Containing Protein from Streptococcus pneumoniae, Protects Mice against Intranasal Pneumococcal Challenge |
| URI | http://iai.asm.org/content/69/6/3827.abstract https://www.ncbi.nlm.nih.gov/pubmed/11349048 https://search.proquest.com/docview/17867967 https://search.proquest.com/docview/70849700 https://pubmed.ncbi.nlm.nih.gov/PMC98401 |
| Volume | 69 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVoJRAXBOUrBYoPHJtsEtuJc1ytqLpIi_bASr1ZdmLTSGw2ItkD_6U_tjNOwnYRXDhGGVtJZmzPxM_vEfKplKJweW5CcLANudEm1JC4hlxXXIqywlUa0RZfs-sN_3IjbsZz3N0Iq2xKU0fNj23U1LceW9luy9mEE5utV4sCqpJkdkJOcsamAn3cOOCcj5NvEULqn4-QLpiFZ8v5MsqKKIuYTGFgSeYRCl4qBjn6YpQAerg2TXzBCJfUHXwxN0hd_C0X_RNS-WCNunpOno3JJZ0PL_GCPLLNGXk8yE3-OiNPVuNG-ktyh2Xn1ngYDF3ftnO6RsKGurmkmm48qStFBpEaljZLV7u-diESWQ16EpMxxcMpFDe2234HM2u572jb2D2Edq3t5WBW9h1dwXRE9Xdo3fV0ic_e6A6edO2NsSVcLCZdl1dkc_X52-I6HIUawlLErA9ZWmkXC2FlYVIjUockbVUhnWYVZAiJtGWeOMjtrDNlnGorXKoTljjUYUylY6_JabNr7FtCoSCHCkrjcdqMW-5MxqskrrIKCmlhuA1IPLlItQMfh_J1TCoVOFhlhcoUOlihg1FkMwnI-eRKpbutqnV9MAvIxZFzD51ipsoKEZCPk7cVjDzcTtGN3e07leSerDD_t0UeS17kcRyQN0N0HHofIy4g4ihufhsg6_fxHRgMnv3bB__5f7Z7R54OIDr8jfSenPY_9_YDZFW9ufDj6B4jRiJH |
| link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagCMqFR6GQAq0PHJtsHnYex9WKahe61R52pd4sO7FpBJtdkeQAv4Ufy4yTsN0KDnCMMo4S-xt7Jv78DSHv85RnJkmUCwOsXaakciUEri6TBUt5XuAqjWyLq3i6Yh-v-XV_jrvuaZVVrkqv-rr2qvLGciu363w08MRGi_kkg6wkGN0nD8BbQz6k6P3WAWOsn34zF4L_pCd1wTw8mo1nXpx5sQfNwLXSyHIUbLEYVOnzsQjQ7dVpUAxGwqSsoc9MV-ziT9HoXVLlrVXq4ilZDt_XkVO-eG2jvPzHHenHf-yAZ-RJH7XScXfzObmnqyPysKtj-f2IPJr3O_QvyE_MZ9fK8mvo4mY7pgtUgiircyrpyqrFUpQmKWHN1HS-aUrjokJWV6hiMKZ46oXijvm22cCUnbc13Va6BZ8ppT7vzPKmpnOY56j8DK3rhs6wSypZw5surDG2hIvJUDDmJVldfFhOpm5fAcLNuR81bhQW0vic6zRToeKhQfW3IkuNjAoIPYJU50lgIGjURuV-KDU3oQyiwGCBxzA10TE5qDaVfk0oZPqQmkk8pxszzYyKWRH4RVxAhs4V0w7xh5EX207oQ9gEKUwF4EbEmYgF4kYgbrB6Z-CQkwEhQtZrUcpyZ-aQ0z3M7B6KIXCUcYecDSAS4NK4TyMrvWlrESRWBTH5u0XipyxLfN8hrzrQ7Z7eA9khfA-Ovw1QTnz_DoDMyopbUJ38Z7szcjhdzi_F5ezq0xvyuGPq4b-qt-Sg-dbqdxC6NerUuuovsF1D0Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LctMwFNVAGTrd8CgvF2i1YFk7fkh-LDOBTAOkkwWZyU4j2VLrgTie2lnAt_Cx3CvbpOnApkuPrzy2fCTdYx2fS8iHPOWZSRLlwgvWLlNSuRISV5fJgqU8L3CVRrXFZXyxZJ9XfNV_umh6WWWVq9Krfqy9qry22sp6nY8GndhoMZ9kwEqCUV2Y0UPyCEZsmAw0vd8-YIz1U3DmAgFIemEXzMWj2XjmxZkXe9jMBX5mdQq2YAw69flYCOj2CjW4BqNoUjbQb6YrePGvjPSusPLWSjV9SlbDM3YCle_etlVe_uuO_eM9OuEZedJnr3TcBTwnD3R1TB539Sx_HpPDeb9T_4L8Rl67VlZnQxfX9Zgu0BGirM6ppEvrGkvRoqSEtVPT-aYtjYtOWV3BiiGY4t8vFHfO63YDU3e-bWhd6S2MnVLq8y4sbxs6h_mOyito3bR0ht1SyQbudGGDsSUcTIbCMS_Jcvrp2-TC7StBuDn3o9aNwkIan3OdZipUPDToAldkqZFRASlIkOo8CQwkj9qo3A-l5iaUQRQYLPQYpiZ6RQ6qTaXfEAqMHyiaxP91Y6aZUTErAr-IC2DqXDHtEH94-6LuDD-EJUphKgA7Is5ELBA7ArGDVTwDh5wMKBGyWYtSlrswh5zu4WZ3UUyFo4w75GwAkoChjfs1stKbbSOCxLohJv-PSPyUZYnvO-R1B7zd1XswO4TvQfJvANqK758BoFl7cQusk3u2OyOHi49T8XV2-eUtOeoEe_jJ6h05aG-2-j1kcK06taP1D7R2RlE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recombinant+PhpA+Protein%2C+a+Unique+Histidine+Motif-Containing+Protein+from+Streptococcus+pneumoniae+%2C+Protects+Mice+against+Intranasal+Pneumococcal+Challenge&rft.jtitle=Infection+and+immunity&rft.au=Zhang%2C+Ying&rft.au=Masi%2C+Amy+W.&rft.au=Barniak%2C+Vicki&rft.au=Mountzouros%2C+Ken&rft.date=2001-06-01&rft.issn=0019-9567&rft.eissn=1098-5522&rft.volume=69&rft.issue=6&rft.spage=3827&rft.epage=3836&rft_id=info:doi/10.1128%2FIAI.69.6.3827-3836.2001&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_IAI_69_6_3827_3836_2001 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0019-9567&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0019-9567&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0019-9567&client=summon |